Kyowa Hakko USA (New York) has earned the 2021 North American New Product Innovation Award for its Immuse Lactococcus lactis strain plasma (LC-Plasma) ingredient by Frost & Sullivan, 2021 New Product Innovation North American Immune-Health Ingredient Industry Best Practices awards.
The lactic acid bacteria ingredient is a clinically backed, patented, non-GMO, GRAS, allergen-free paraprobiotic that was developed by Kirin Holding Co. Ltd. Paraprobiotics are defined as non-viable probiotis or inactive probiotics that confer benefits such as immune support. Backed by clinical research, Immuse provides innate and adaptive immune support by activating immune cells.
“Immuse is backed by twenty-six studies, including 11 human clinical trials that comprise nine efficacy studies and two safety studies, making it one of the most comprehensively studied and clinically validated paraprobiotics ingredients” explained Smriti Sharma, senior industry analyst, in a press release.
Shintaro Ichikawa, PhD, director of technical affairs at Kyowa Hakko USA, who led the development and product launch of Immuse, said in a press release: “Immuse is unlike any other immune support ingredient, by activating pDC’s, key leaders of the immune system, Immuse provides more comprehensive immune support.”
Safety studies indicate that the strain is well-tolerated at a high dosage (250 mg/d). It is also used in numerous product applications such as drinks, yogurt, and other functional food and beverages.